Therapeutic Drug Monitoring Guides the Management of Crohn’s Patients with Secondary Loss of Response to Adalimumab.

Therapeutic Drug Monitoring Guides the Management of Crohn’s Patients with Secondary Loss of Response to Adalimumab. Inflamm Bowel Dis. 2018 Apr 13;: Authors: Restellini S, Chao CY, Lakatos PL, Aruljothy A, Aziz H, Kherad O, Bitton A, Wild G, Afif W, Bessissow T Abstract Background: Managing loss of response (LOR) in Crohn’s disase (CD) patients remains challenging. Compelling evidence supports therapeutic drug monitoring (TDM) to guide management in patients on infliximab, but data for other biologics are less robust. We aimed to asses if empiric dose escalation led to improved…

Read More

Circulating and Fecal microRNAs as Biomarkers for Inflammatory Bowel Diseases.

Circulating and Fecal microRNAs as Biomarkers for Inflammatory Bowel Diseases. Inflamm Bowel Dis. 2018 Apr 12;: Authors: Schönauen K, Le N, von Arnim U, Schulz C, Malfertheiner P, Link A Abstract Background: Assessment of the disease activity in inflammatory bowel disease (IBD) is essential for adequate treatment management and reliable noninvasive biomarkers for verification of mucosal healing are still needed. MicroRNAs (miRNAs) are differentially expressed in IBD and cancer. We aimed to evaluate the potential of circulating and fecal miRNAs as diagnostic biomarkers for IBD. Methods: In this proof-of-principle study…

Read More

Telemedicine and Mobile Health Technology Are Effective in the Management of Digestive Diseases: A Systematic Review.

Related Articles Telemedicine and Mobile Health Technology Are Effective in the Management of Digestive Diseases: A Systematic Review. Dig Dis Sci. 2018 Apr 16;: Authors: Helsel BC, Williams JE, Lawson K, Liang J, Markowitz J Abstract BACKGROUND: Mobile applications and interactive websites are an increasingly used method of telemedicine, but their use lacks evidence in digestive diseases. AIM: This study aims to explore digestive disease studies that use telemedicine to effectively manage disease activity, help monitor symptoms, improve compliance to the treatment protocol, increase patient satisfaction, and enhance the patient-to-provider…

Read More

Antenatal Management for Women with Inflammatory Bowel Disease: Experience from Our ‘IBD MOM’ Clinic.

Related Articles Antenatal Management for Women with Inflammatory Bowel Disease: Experience from Our ‘IBD MOM’ Clinic. Dig Dis Sci. 2018 Apr 06;: Authors: Shitrit AB, Cohen Y, Hassin O, Ya’acov AB, Farkash R, Koslowsky B, Milgrom Y, Livovsky DM, Samueloff A, Goldin E, Grisaru-Granovsky S Abstract BACKGROUND: Inflammatory bowel disease affects women during their reproductive years and thus pregnancy outcomes. IBD MOM is a multidisciplinary, single-center clinic established to benefit women with IBD and their neonates. AIM: The aim of this study was to evaluate the perinatal outcomes of the…

Read More

ACG Clinical Guideline: Management of Crohn’s Disease in Adults.

Related Articles ACG Clinical Guideline: Management of Crohn’s Disease in Adults. Am J Gastroenterol. 2018 Apr;113(4):481-517 Authors: Lichtenstein GR, Loftus EV, Isaacs KL, Regueiro MD, Gerson LB, Sands BE Abstract Crohn’s disease is an idiopathic inflammatory disorder of unknown etiology with genetic, immunologic, and environmental influences. The incidence of Crohn’s disease has steadily increased over the past several decades. The diagnosis and treatment of patients with Crohn’s disease has evolved since the last practice guideline was published. These guidelines represent the official practice recommendations of the American College of Gastroenterology…

Read More

Proactive infliximab monitoring following reactive testing is associated with better clinical outcomes than reactive testing alone in patients with inflammatory bowel disease.

Proactive infliximab monitoring following reactive testing is associated with better clinical outcomes than reactive testing alone in patients with inflammatory bowel disease. J Crohns Colitis. 2018 Mar 24;: Authors: Papamichael K, Vajravelu RK, Vaughn BP, Osterman MT, Cheifetz AS Abstract Background and aims: Reactive testing has emerged as the new standard of care for managing loss of response to infliximab in inflammatory bowel disease (IBD). Recent data suggest that proactive infliximab monitoring is associated with better therapeutic outcomes in IBD. Nevertheless, there are no data regarding the clinical utility of…

Read More

Role of Positron Emission Tomography in Assessing Disease Activity in Ulcerative Colitis: Comparison with Biomarkers.

Role of Positron Emission Tomography in Assessing Disease Activity in Ulcerative Colitis: Comparison with Biomarkers. Dig Dis Sci. 2018 Mar 21;: Authors: Berry N, Sinha SK, Bhattacharya A, Prasad KK, Vaishnavi C, Vaiphei K, Samanta J, Prasada R, Dhaka N, Kochhar R Abstract BACKGROUND: Disease activity in ulcerative colitis (UC) is best assessed clinically by Mayo score. 18-Fluorodeoxyglucose positron emission tomography-computerized tomography (FDG PET-CT) is a noninvasive imaging technique to assess extent, disease activity and response to treatment of UC, especially in high risk population or patients unwilling for endoscopy.…

Read More
<< Go Back